On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the moment they decide what to test. The price was not disclosed, so the strategy is the story.
Software That Feeds the Lab
Start with the customer base IDEXX already has. More than 10,000 clinics worldwide run on its cloud practice software, and CoVet will plug into that system, including a link to IDEXX VetConnect PLUS. That hands a new product a ready audience. CoVet also works with practice systems IDEXX does not make, and IDEXX plans to keep supporting rival scribes, so the tool can reach clinics and regions the company does not serve today.
Then there is the engine this could feed. On August 4, IDEXX reported second-quarter revenue growth of 10%, and its recurring diagnostics business grew 11%, powered by higher volumes. That says vets are already running more tests, which is the behavior a smarter workflow tool is meant to encourage. The company also placed more than 1,600 inVue Dx analyzers in the quarter, lifting the installed base past 9,000, and it counts that instrument among its AI-driven products. Software and hardware are pointing in the same direction.
The Blanks in the Deal
The biggest problem is what we can’t see. Without deal terms, there is no way to judge what IDEXX paid or how much CoVet matters to earnings. And the company describes the payoff in future tense, saying these capabilities can raise diagnostic use over time. That is a hope, not a result yet. CoVet’s openness to other systems cuts both ways too. It widens reach, but it also means a clinic can use CoVet without going deeper into IDEXX’s ecosystem.
The second quarter also needs a careful read. Earnings per share rose 18%, but that included tax benefits from stock-based pay and a currency boost, and growth on a comparable basis was 15%. Some of the gain, in other words, did not come from selling more to vets. IDEXX also says it is spending more on commercial and innovation priorities, so its higher full-year earnings outlook comes with added costs attached.
Calm Money, Full Price
Hedge fund ownership of IDEXX rose to 63 funds from 62 in the prior quarter. That is a tiny gain, so read it as steady conviction, not a stampede. Short interest is 3.04% of float, which means very few investors are betting against the stock. The forward P/E of 30.86, as of September 18, shows investors are paying up for expected earnings growth. That leaves little cushion if results slip.
A Payoff Still on Layaway
The tension here is between a plausible strategy and a benefit nobody can measure yet. If clinics that adopt CoVet end up ordering more tests, the deal will look smart against a business already growing on volume. If the benefits stay in the brochure, it becomes one more cost sitting under a stock that carries a full price. Test volumes at CoVet clinics are the number to watch.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
